Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idec Zevalin NHL Indication Split By Accelerated/Standard Approval

Executive Summary

Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements
Advertisement

Related Content

GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GSK/Corixa Bexxar User Fee Deadline Extended To Review Safety Database
CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Zevalin Medicare Reimbursement: Idec Predicts Smooth Transition Into 2003
Idec Zevalin EU delay
Idec Zevalin Targets Up To 40,000 Rituxan-Refractory NHL Patients
Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica
Idec Zevalin Clears Cmte.: Non-Refractory Use May Be Accelerated Approval
Idec Zevalin Clears Cmte.: Non-Refractory Use May Be Accelerated Approval
Advertisement
UsernamePublicRestriction

Register

PS039381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel